Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
198
days
Endothelial Cells Contribute to the Immune-Vascular Milieu Characterizing VETC+ HCC
Authors
Barbara Durante; Simone Zanella; Francesco de Napoli; Beatrice Esposito; Camilla De Carlo; Reha Akpinar; Cristina Richichi; Francesca Lazzaroni; Barbara Franceschini; Cristiana Soldani; Fabio Grizzi; Fabio Pasqualini; Ana Lleo; Guido Torzilli; Fabio Procopio; Luca Viganò; Salvatore Piscuoglio; Charlotte K.Y. Ng; Federica Airi; Elvezia Paraboschi; Ines Simeone; Luca Di TommasoShow moreShow less
Affiliations
1. Pathology Unit, IRCCS Humanitas Research Hospital, Milan, Italy; 2. Department of Biomedical Sciences, Humanitas University, Milan, Italy; 3. Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy; 4. Hepatobiliary Immunopathology Lab, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; 5. Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy; 6. Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; 7. Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Rozzano, Italy; 8. Hepatobiliary Unit, Department of Minimally Invasive General and Oncologic Surgery, Humanitas Gavazzeni University Hospital, Bergamo, Italy; 9. Department of Electrical Engineering and Information Technologies, University of Naples “Federico II”, Naples, ItalyShow moreShow less
134
days
Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study
Authors
Xiao-Wu Zhang; Li-Wei Deng; Yin-Gen Luo; Yin-Fa Xie; Rui-Bao Liu; Hai-Bo Shao; Tong-Guo Si; Dui-Ping Feng; Jian Wang; Yu Zhang; Qing-Dong Li; Hong-Tao Hu; Wei-Jun Fan; Peng Song; Li-Nan Yin; Yan Wang; Yi Chen; Tian-Shi Lv; Yong Xie; Tian-Yi Hua; Jing Xiao; Rui-Can Nie; Lu-Jun Shen; Zhi-Ming Xuan; Chang Liu; Xue-Gang Yang; Xu Chang; Xiao LiShow moreShow less
Affiliations
1. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2. Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 3. Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China; 4. Department of Interventional Radiology, The First Hospital of China Medical University, Liaoning, China; 5. Department of Interventional Treatment, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer , Tianjin, China; 6. Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China; 7. Department of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Shanxi Provincial Clinical Research Center for Interventional Medicine, Taiyuan, China; 8. Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China; 9. Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; 10. Vascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, China; 11. Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 12. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China; 13. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China; 14. Intervention Center, West China Hospital, Sichuan University, Chengdu, China; 15. Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, ChinaShow moreShow less
125
days
Baseline Predictors, Prognostic Impact, and Risk Stratification of Early Progressive Disease on Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study
Authors
Takuya Sho; Goki Suda; Tamami Abe; Masashi Ninomiya; Kei Endo; Yudai Fujiwara; Hiroshi Numao; Go Igarashi; Mio Tsuruoka; Chikara Iino; Kenta Yoshida; Satoshi Sato; Masato Nakai; Masatsugu Ohara; Takashi Kitagataya; Naoki Kawagishi; Tomohiro Katsumi; Keita Maki; Wataru Sato; Shinichiro Minami; Kazumichi Abe; Masashi Fujita; Yoshiya Yamamoto; Masaru Baba; Takashi Meguro; Takayoshi Oikawa; Nobukazu Tanabe; Yoshiyuki Ueno; Naoya Sakamoto; Hidekatsu Kuroda; for NORTH Japan HCC study groupShow moreShow less
Affiliations
1. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2. Division of Internal medicine, Department of Gastroenterology and Hepatology, Iwate Medical University, Morioka, Japan; 3. Divison of Gastroenterology, Tohoku University Hospital, Sendai, Japan; 4. Aomori Prefectural Central Hospital, Aomori, Japan; 5. Department of Gastroenterology, Hematology and Clinical immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 6. Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan; 7. Department of Gastroenterology, Akita University Graduate School of Medicine, Akita, Japan; 8. Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan; 9. Hakodate City Hospital, Hakodate, Japan; 10. Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Sapporo, Japan; 11. Hokkaido Gastroenterology Hospital, Sapporo, Japan; 12. Japanese Red Cross Morioka Hospital, Morioka, Japan; 13. Department of Gastroenterology, NHO Sendai Medical Center, Sendai, JapanShow moreShow less
339
days
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma
Authors
Lorenza Rimassa; Farshid Dayyani; Robin K. Kelley; Bruno Sangro; Stephen L. Chan; Hitomi Nakamura; Lucy Clark; Ioannis Xynos; Ghassan K. Abou-AlfaShow moreShow less
Affiliations
1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; 2. Hepatopancreatobiliary Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy; 3. Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Orange, CA, USA; 4. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; 5. Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain; 6. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR; 7. Global Medical Affairs, AstraZeneca, Cambridge, UK; 8. Oncology R&D, AstraZeneca, Cambridge, UK; 9. Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK; 10. Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA; 11. Weill Medical College, Cornell University, New York, NY, USA; 12. Trinity College Dublin, Dublin, IrelandShow moreShow less
189
days
Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan
Authors
Toshihiro Tanaka; Hiroshi Anai; Tetsuya Masada; Satoru Sueyoshi; Takeshi Sato; Shohei Toyoda; Takeshi Matsumoto; Yuto Chanoki; Keisuke Oshima; Sho Shimizu; Mariko Irizato; Ryosuke Taiji; Kiyoyuki Minamiguchi; Hideki Kunichika; Hiroyuki Kurakami; Shigeo Ichihashi; Hideyuki NishiofukuShow moreShow less
Affiliations
1. Diagnostic and Interventional Radiology, Nara Medical University, Kashihara, Japan; 2. Nara City Hospital, Sakurai, Japan; 3. Nara Prefectural General Medical Center, Sakurai, Japan; 4. Saiseikai-Chuwa Hospital, Sakurai, Japan; 5. Institute for Clinical and Translational Science, Nara Medical University, Sakurai, JapanShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days